Related Experiment Video
Updated: Feb 28, 2026

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome
Preetesh Jain1, Sa Wang2, Keyur P Patel2
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Abstract:
Mast cell leukemia (MCL) is a very rare subtype of systemic mastocytosis (SM). We have identified 13 such patients (5.9%) among 218 patients with SM seen at our institution between 1994 and 2016. Patients with MCL had poor survival (median 31.6 months); response to various therapies was rare and not durable. Clinical course may be affected by concurrent associated hematologic neoplasm and different genetic profiles. More research is required to decipher this rare and enigmatic SM subtype.
Related Concept Videos
Cancer Survival Analysis
Kaplan-Meier Approach

